Skip to content
Home/Companies/Biotech/Semarion
Semarion

Semarion

Biotech·UK·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Semarion?

Semarion is currently owned by Parkwalk Advisors through Parkwalk Opportunities EIS Fund (2009 vintage), since 2022.

Hand-verified · updated 2026-07-16

Parkwalk Advisors
Investor
Parkwalk Advisors
Parkwalk Opportunities EIS Fund · 2009 · VC

Key facts

HQUK
SectorBiotech
StatusActive
Websitewww.semarion.com

More from Parkwalk Opportunities EIS Fund

Other portfolio companies in the same fund.

1715 Labs
Exited 2023
AI/MLUK
ACAL Energy
Exited 2017
EnergyUK
Aqdot
Aqdot
Active
Deep TechUK
Arkivum
Arkivum
Active
SoftwareUK
Arvia
Arvia
Active
ClimateTechUK
Cytotrait
Active
BiotechUnited Kingdom· 2026

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Semarion

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Semarion.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue